Hepatorenal Syndrome Treatment Market Report 2026

The hepatorenal syndrome treatment market size has grown strongly in recent years. It will grow from $15.17 billion in 2025 to $16.1 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to limited awareness of hrs, lack of standardized treatment protocols, high mortality associated with liver failure, dependency on conventional dialysis methods, restricted access to advanced therapeutics.

The hepatorenal syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $21.12 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to advancements in targeted therapies, adoption of precision medicine approaches, expansion of healthcare infrastructure, integration of ai and digital tools in patient monitoring, increased investment in novel drug development. Major trends in the forecast period include increasing prevalence of chronic liver diseases, advancements in renal replacement therapies, personalized treatment approaches for hrs, growth in hospital and clinical infrastructure, rising focus on early diagnosis and monitoring.

The increase in fast-track and novel drug designations is anticipated to drive the growth of the hepatorenal syndrome treatment market in the coming years. Fast-track and novel drug designations are regulatory pathways intended to accelerate the development, review, and approval of therapies for serious conditions with unmet medical needs, enabling patients to access innovative treatments sooner. The growing number of such designations supports faster development of therapies for hepatorenal syndrome by addressing the urgent demand for effective treatment options, improving potential patient outcomes, and closing existing treatment gaps. For example, in January 2024, according to the New Drug Therapy Approvals 2023 report published by the Center for Drug Evaluation and Research, a US-based division of the U.S. Food and Drug Administration, 55 novel drugs were approved in 2023, of which 20, or 36%, were classified as first-in-class, compared with 37 novel drug approvals in 2022. Consequently, the rising number of fast-track and novel drug designations is contributing to the expansion of the hepatorenal syndrome treatment market.

The growth of the hepatorenal syndrome treatment market is also being supported by rising healthcare spending. Healthcare spending represents the total expenditure across all healthcare sectors within an economy, including hospitals, home healthcare services, prescription medicines, nursing facilities, and individual healthcare services. Increased healthcare expenditure can lead to greater investment in research and development of more effective hepatorenal syndrome therapies, as well as improved access to screening tools and earlier diagnosis, which may result in timelier treatment and better patient outcomes. For example, in April 2025, according to the Office for National Statistics, a UK-based independent producer of official statistics, total healthcare expenditure increased by 6.5% in nominal terms and 2.4% in real terms between 2023 and 2024, while healthcare spending as a share of GDP remained stable at 11.1% in 2024. Therefore, rising healthcare spending is further driving the growth of the hepatorenal syndrome treatment market.

Major companies operating in the hepatorenal syndrome treatment market are concentrating on the development of innovative solutions such as vasoconstrictive renal-support therapies to improve kidney function and clinical outcomes in patients experiencing rapid deterioration due to advanced liver disease. Vasoconstrictive renal-support therapies are pharmacological treatments designed to enhance renal perfusion and support kidney recovery by selectively constricting splanchnic blood vessels and stabilizing systemic circulation. For instance, in June 2024, Mallinckrodt plc presented new clinical data on TERLIVAZ, a terlipressin injection approved for hepatorenal syndrome associated with rapid kidney function decline. The data demonstrated favorable outcomes across multiple patient subgroups, including higher rates of kidney function reversal and a reduced need for renal replacement therapy, highlighting the therapy’s role in managing a life-threatening complication of advanced liver disease and supporting improved clinical decision-making.

Major companies operating in the hepatorenal syndrome treatment market are BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, Baxter International Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Boehringer Ingelheim GmbH, Bayer AG, Gilead Sciences Inc., Pfizer Inc., AstraZeneca PLC, AbbVie Inc., Amgen Inc., F Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd, Astellas Pharma Inc., Kyowa Kirin Co Ltd.

North America was the largest region in the hepatorenal syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hepatorenal syndrome treatment market during the forecast period. The regions covered in the hepatorenal syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatorenal syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the hepatorenal syndrome treatment market by increasing the cost of imported therapeutics, dialysis equipment, and precision medical devices. Segments such as therapeutics and dialysis, particularly in regions like North America and Europe that rely on imported medical supplies, are most affected. However, tariffs are encouraging local manufacturing and supply chain diversification, potentially leading to reduced dependency on imports and fostering innovation in cost-effective HRS treatment solutions.

The hepatorenal syndrome treatment market research report is one of a series of new reports that provides hepatorenal syndrome treatment market statistics, including hepatorenal syndrome treatment industry global market size, regional shares, competitors with a hepatorenal syndrome treatment market share, detailed hepatorenal syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hepatorenal syndrome treatment industry. This hepatorenal syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatorenal syndrome (HRS) is a multiorgan disorder characterized by acute kidney injury in patients with severe liver disease. Patients with this syndrome display signs and symptoms of liver failure in addition to decreased urination when they become oliguric.

The main types of hepatorenal syndrome treatment include type 1 hepatorenal syndrome and type 2 hepatorenal syndrome. Type 2 hepatorenal syndrome is distinguished by a moderate and steady decline in glomerular filtration rate, and it frequently affects people whose liver function is still mostly intact. They are treated by providing therapeutics and surgical treatment for use in various end-users such as hospitals and clinics, ambulatory surgical centers, academic and research institutes and others.

The hepatorenal syndrome treatment market includes revenues earned by providing imaging, blood, and urine tests to evaluate the patient's liver and kidney function. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.